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erson@eAbstract Aim: Improving survival for women with early breast cancer (eBC) requires greater
attention to the consequences of treatment, including risk to ovarian function. We have
assessed whether biochemical markers of the ovarian reserve might improve prediction of che-
motherapy related amenorrhoea.
Methods: Women (n = 59, mean age 42.6 years [(range 23.3–52.5]) with eBC were recruited
before any treatment. Pretreatment ovarian reserve markers (anti-Mu¨llerian hormone
[AMH], follicle-stimulating hormone [FSH], inhibin B) were analysed in relation to ovarian
status at 2 years.
Results: Pretreatment AMH was signiﬁcantly lower in women with amenorrhoea at 2 years
(4.0 ± 0.9 pmol/L versus 17.2 ± 2.5, P < 0.0001), but FSH and inhibin B did not differ
between groups. By logistic regression, pretreatment AMH, but not age, FSH or inhibin B,
was an independent predictor of ovarian status at 2 years (P = 0.005; odds ratio 0.013). Wehe Authors. Published by Elsevier Ltd. All rights reserved.
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R.A. Anderson et al. / European Journal of Cancer 49 (2013) 3404–3411 3405combined these data with a similar cohort (combined n = 75); receiver–operator characteristic
analysis for AMH gave area under curve (AUC) of 0.90 (95% conﬁdence interval (CI) 0.82–
0.97)). A cross-validated classiﬁcation tree analysis resulted in a binary classiﬁcation schema
with sensitivity 98.2% and speciﬁcity 80.0% for correct classiﬁcation of amenorrhoea.
Conclusion: Pretreatment AMH is a useful predictor of long term post chemotherapy loss of
ovarian function in women with eBC, adding signiﬁcantly to the only previously established
individualising predictor, i.e. age. AMH measurement may assist decision-making regarding
treatment options and fertility preservation procedures.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Recent years have seen a steady improvement in the
long-term survival for many malignancies, including
early breast cancer (eBC).1 Consideration of the late
eﬀects of treatment is therefore assuming greater prom-
inence. Chemotherapy has long been recognised to have
adverse eﬀects on ovarian function,2–4 although detailed
understanding of the eﬀects of chemotherapy on the
ovary is less abundant.5,6 A survival beneﬁt of chemo-
therapy-related amenorrhoea has been suggested in
breast cancer,7,8 although the risk of amenorrhoea could
reﬂect individual responsiveness to chemotherapy.9 For
premenopausal women with moderate risk of eBC, there
is a risk beneﬁt assessment to be made about whether to
undergo chemotherapy, and for many, potential loss of
fertility/ovarian function may inﬂuence their choice of
adjuvant therapies.
Age at treatment is a clearly identiﬁed risk factor for
the development of amenorrhoea3,4 reﬂecting the pro-
gressive decline in the ovarian reserve.10,11 There is how-
ever very large variation in follicle number between
women of the same age, thus there is a need for a reliable
marker to allow improved individualisation of advice to
women facing potentially curative cancer therapy that
will signiﬁcantly aﬀect treatment decisions related to sub-
sequent reproductive function. There is now a substantial
body of evidence indicating that serum measurement of
anti-Mu¨llerian hormone (AMH) is a clinically useful
biomarker of the ovarian reserve.12–15 It is a more accu-
rate predictor than other hormonal markers of the ovar-
ian reserve (follicle-stimulating hormone (FSH), inhibin
B),13,16 and its stability across the menstrual cycle is of
practical value.17 It is however sensitive to long-term
gonadotrophin suppression e.g. by gonadotrophin-
releasing hormone (GnRH) analogues18 and the contra-
ceptive pill.19 While it is probably of similar value to
ultrasound determination of antral follicle count the lat-
ter is less readily available and requires expertise to max-
imise accuracy.20 A number of studies have demonstrated
that AMH is lower in women who have had cancer
treatment18,21–25 but the predictive value of AMH for
post-chemotherapy amenorrhoea is unclear.26–28
We have therefore carried out a prospective study to
test the hypothesis that AMH, measured at the time of
diagnosis, would be a clinically useful predictor ofamenorrhoea after chemotherapy for eBC, in compari-
son to age at diagnosis or other biochemical markers
of the ovarian reserve.16 As some women show recovery
of ovarian function after chemotherapy, the primary
analysis of this study was performed at two years after
diagnosis.
2. Patients and methods
A total of 60 premenopausal women with early breast
cancer were recruited to this study, between March 2007
and June 2009, in two centres (Edinburgh Breast Unit
and Copenhagen University Hospital – Rigshospitalet):
one woman was withdrawn as she was found to be inel-
igible, thus data were available for 59 women. The study
received Ethics committee approval, and all women gave
informed consent in writing. The design of the study was
prospective, with women recruited before receiving any
treatment for their breast cancer, and followed up for
a total of 2 years. Inclusion criteria were primary opera-
ble breast cancer without evidence of metastases, and
being premenopausal assessed by regular menses in the
absence of sex steroid contraception, or premenopausal
gonadotrophin and estradiol concentrations. Women
were not included if they had had previous surgery to
either ovary or had received chemotherapy previously.
Recruitment to this study did not alter the management
of their breast cancer, and women were still considered
for any interventional research study for which they
might also be eligible.
The mean age of the women was 42.6 years (range
23.3–52.5). Of the 59 women in this study, a total of
13 withdrew before the end of the study 2 years later
(Fig. 1). This was for reasons of disease recurrence in
three, four had an oophorectomy and/or hysterectomy
and for personal reasons in six. Data were available
for analysis from 55 women at 1 year and 46 at 2 years.
Table 1 gives details of chemotherapy regimens; 44
women received tamoxifen treatment following chemo-
therapy, and seven received goserelin (only one woman
received goserelin but not tamoxifen) and one woman
was treated with anastrozole in addition to tamoxifen.
Women kept menstrual diaries throughout, with data
subsequently coded as amenorrhoea when there had
been no bleeding in the previous 6 months, or as having
on-going menses. The primary end-point of the study
60 women recruited
59 women included
1 woman excluded: 
ineligible
55 women at 1 year
46 women at 2 years
4 women withdrew before 
1 year: 
disease recurrence (n=1)
oophorectomy (1)
choice (2)
9 woman withdrew before 
2 years: 
disease recurrence (2) 
hyst/oophorectomy (3)
choice (4)
Chemotherapy (table 1)
Endocrine therapy
Tamoxifen (44)
Tamoxifen +Goserelin (6)
Tamoxifen+anastrozole (1)
Goserelin (1)
Fig. 1. Consort diagram showing patient numbers at recruitment, at
key points during the study, and reasons for withdrawal from the
study.
3406 R.A. Anderson et al. / European Journal of Cancer 49 (2013) 3404–3411was of amenorrhoea versus ongoing menses at 2 years.
Blood samples were obtained pretreatment, after one
and two cycles of chemotherapy, and at 1 year, and were
scheduled to be in the early follicular phase (days 2–5) in
women with ongoing menses.
Serum hormones were measured as previously
described18 with the exception of AMH which was mea-
sured by the Gen II enzyme-linked immunosorbent
assay (ELISA) kit (Beckman Coulter, Chaska, MN).
This has a sensitivity of 0.16 ng/ml (1.1 pmol/L) and
in-house intra- and inter-assay coeﬃcient of variation
of <6%.
2.1. Statistical analysis
Data are presented as mean ± standard error of
mean (SEM), and range when speciﬁed. Spearman’s testTable 1
Details of chemotherapy regimens.
Regimen Component drugs
Non-trial
FEC 5FU, epiribucin + cyclophosphamide
FEC-T FEC followed by docetaxel
E-CMF Epirubicin q 21 d followed by CMF
EC-T Epirubicin + cyclophosphamide followed by docet
TC Docetaxel with cylophosphamide
TACT2 trial
E-cCMF (TACT2) Epirubicin q 21 d followed by CMF
E-CAP Epirubicin q 21 d followed by capecitabine
Accelerated E-cCMF Epirubicin q 14 d followed by CMF
cCMF: classical Bonnadona. CMF: cyclophosphamide, methotrexate, 5 ﬂuwas used to test relationships between age and AMH
pretreatment and other pairs of variables. Initial analy-
sis of predictors of amenorrhoea (i.e. the primary objec-
tive of the study) was performed by Student’s t test, with
log transformation of hormonal data to correct for het-
erogeneity of variance. Because of relationships between
the variables, a multivariate logistic regression analysis
was performed to determine which factors indepen-
dently predicted amenorrhoea. Analyses were per-
formed using SPSS (version 20; IBM Corporation).
To improve the power of the analysis we combined
this dataset in a secondary analysis with a previous very
similar cohort of premenopausal women with eBC
recruited with the same inclusion and exclusion crite-
ria18,27 for which pretreatment AMH and amenorrhoea
versus menses at 2 years was also available. In that study
AMH had been measured using a diﬀerent ELISA: data
were converted as described elsewhere.29 The relative
predictive importance of AMH and age in the combined
cohort of 75 women was investigated using two distinct
methods:
(1) Analysis of the area under curve (AUC) of recei-
ver–operator characteristic (ROC) plots30 for age
and AMH as separate predictors.
(2) The use of Random Forests31 to derive 2000 clas-
siﬁcation trees each of which uses age and AMH to
predict amenorrhoea. To estimate the relative
importance of age and AMH, we calculated the
total decrease in node impurities (measured by
the Gini index) from splitting on each variable,
averaged over all trees.
We also performed a top-down induction of a classi-
ﬁcation tree32 using both age and AMH as potential
classiﬁers. The induction was done in two stages. We
ﬁrst derived the classiﬁcation tree by recursive identiﬁca-
tion of the predictor variable that splits the data into
two groups, so that the tradeoﬀ between sensitivity
and speciﬁcity is optimal. We then performed a 10-foldNo. of
women
Duration
(weeks)
Cyclophosphamide
regimen
Cycles of
taxane
4 18 3000 mg/m2 over 18 weeks 0
26 18 1500 mg/m2 over 9 weeks 3
16 24 3000 mg/m2 over 12 weeks 0
axol 6 18 1800 mg/m2 over 18 weeks 3
1 18 3600 mg/m2 over 18 weeks 6
3 28 4800 mg/m2 over 16 weeks 0
2 24 0 0
3 24 4800 mg/m2 over 16 weeks 0
orouracil.
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order to minimise the error rate when generalised to
unseen observations, and converted it into a classiﬁca-
tion mosaic chart. The ROC, Random Forest and clas-
siﬁcation tree analyses were performed using R (version
2.15.1, The R Foundation for Statistical Computing).3. Results
At pretreatment, there was an inverse relationship
between age and serum AMH (Spearman rho = 0.56,
P < 0.0001; Fig. 2a). AHM fell during chemotherapy,
from 7.9 ± 1.3 pmol/L pretreatment to 3.5 ± 0.7 pmol/
L after one cycle (P < 0.001). There was a signiﬁcant
relationship between pretreatment AMH and that after
the ﬁrst cycle of chemotherapy (rho = 0.76,
P < 0.0001; Fig. 2b), indicating that after one cycle of
chemotherapy AMH remained higher in women with a
higher pretreatment AMH. However after two or more
cycles and at 1 year, AMH was undetectable or close to
the limit of detection in all women. To test whether
younger women might have received lower doses of
cyclophosphamide, the relationship between age and0
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Fig. 2. (A) Pretreament anti-Mu¨llerian hormone (AMH) versus age in
women with newly-diagnosed early breast cancer (n = 59). Spearman
rho = 0.56, P < 0.0001. (B) Relationship between AMH pretreat-
ment and after one cycle of chemotherapy (Spearman rho = 0.76,
P < 0.0001). Red symbols indicate women subsequently demonstrated
to have ongoing menses at 2 years, blue, those with amenorrhoea at
that time, black, those who withdrew from the study before 2 years.dose (total dose received in mg/m2) was calculated.
There was no relationship between age and dose of
cyclophosphamide (P = 0.57).
The primary objective of this study was the assess-
ment of pretreatment AMH in comparison with other
markers of the ovarian reserve as a predictor of post-
chemotherapy ovarian function, using amenorrhoea at
2 years as an indicator of absent ovarian activity. We
have previously robustly validated this using a full panel
of endocrine and ultrasound markers,27 conﬁrmed by
the present data as serum estradiol was signiﬁcantly
lower in women with amenorrhoea versus ongoing men-
ses (91 ± 19 versus 302 ± 143 pmol/L, P = 0.001).
At 2 years, 30 women were amenorrhoeic and nine
had ongoing menses (after excluding women taking
goserelin). Pretreatment AMH showed a signiﬁcant
positive correlation with menses; women with low pre-
treatment AMH were more prone to be amenorrhoeic
at 2 years (Fig. 3a; Table 2). Age at diagnosis was also
signiﬁcantly diﬀerent between these groups, being higher
in those developing amenorrhoea, but pretreatment
FSH and inhibin B were not signiﬁcantly diﬀerent
(Fig. 3b–d). At 1 year, 45 women were amenorrhoeic
whereas 10 had ongoing menses. Similar results were
obtained to those seen at 2 years (Table 2), with mean
pre-treatment AMH concentrations lower in amen-
orrhoeic women. Age was also signiﬁcantly diﬀerent
but FSH and inhibin B were again not diﬀerent. These
data therefore indicate that both pre-treatment AMH
and age are predictors of amenorrhoea at both post-
treatment time points analysed.
As FSH and inhibin B are established markers of the
ovarian reserve,16 logistic regression was used to investi-
gate which variables have independent predictive value.
Age and pretreatment concentrations of AMH, FSH
and inhibin B were included in the analysis. Only
AMH remained a signiﬁcant predictor of amenorrhoea
at 24 months (P = 0.005) with odds ratio 0.013 (95%
conﬁdence interval (CI) 0.001–0.227). Age, FSH and
inhibin B were not signiﬁcant predictors.
Using the combined datasets (Table 3), the relative
importance of age and AMH as predictors, calculated
using Random Forests, showed that age was slightly less
important than AMH (14.1 mean decrease in Gini index
for age; 14.5 mean decrease in Gini index for AMH).
The AUC of the ROC plot for AMH was 0.90 (95%
CI 0.82 – 0.97)); the AUC of the ROC plot forage was
0.88 (95% CI 0.78–0.97) (Fig. 4), again indicating that
both variables are important, with AMH slightly more
important than age.
This secondary analysis indicated that predictive
models derived using either age or AMH alone would
be inferior to predictive models that incorporated both
factors. We therefore derived a classiﬁcation mosaic
chart, shown in Fig. 5. This binary classiﬁcation
schema has sensitivity 98.2% and speciﬁcity 80.0%. The
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Fig. 3. Pretreatment concentrations of anti-Mu¨llerian hormone (AMH), follicle-stimulating hormone (FSH) and inhibin B and age by the presence
of amenorrhoea or ongoing menses at 2 years. Mean ± standard error of mean (SEM), n = 37 and n = 9 respectively. *P = 0.004; **P < 0.0001.
Table 2
Pretreatment age and ovarian reserve markers by amenorrhoea/
ongoing menses at 1 and 2 years.
Amenorrhoea Ongoing
menses
P
At 1 year
Age (years) 43.3 ± 0.7 37.9 ± 0.8 0.03
Anti-Mu¨llerian hormone
(AMH) (pmol/L)
6.6 ± 1.5 16.6 ± 4.8 0.01
Follicle-stimulating hormone
(FSH) (IU/L)
4.9 ± 0.6 3.6 ± 0.9 ns
Inhibin B (pg/ml) 37.6 ± 5.8 32.4 ± 12.0 ns
At 2 years
Age (years) 43.9 ± 0.8 37.9 ± 2.0 0.004
AMH (pmol/L) 4.0 ± 0.9 17.2 ± 5.1 <0.0001
FSH (IU/L) 5.6 ± 0.8 3.3 ± 0.5 ns
Inhibin B (pg/ml) 34.2 ± 6.2 38.1 ± 14.6 ns
Table 3
Demographic details of combined cohort (n = 75).
Age (year) 42.8 ± 0.7
Ethnicity (n) 73 Caucasian, one Asian, one Hispanic
Age at menarche (year) 13.0 ± 0.2
Previous pregnancies (n)
None 14
First trimester only 2
Live birth 59
Current smoker (n) 15
Weight (kg) 69.0 ± 1.7
Fig. 4. Receiver–operator characteristic (ROC) curve analysis of anti-
Mu¨llerian hormone (AMH) and age as predictors of ovarian function
(indicated by ongoing menses) at 2 years (combined cohort: n = 75).
Area under the curve for AMH (red):0.90 (95% conﬁdence interval
(CI) 0.82–0.97); for age (blue), 0.88 (95% CI 0.78–0.97).
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subjects into three classes based on pretreatment AMH:
low AMH subjects are classiﬁed as likely to develop
amenorrhoea, and high AMH subjects are classiﬁed aslikely to have ongoing menses. The medium AMH group
is split into two classes at age 38.6 years; above this age
threshold predicts amenorrhoea, and below predicts
ongoing menses. If the clinical context requires that sen-
sitivity be maximised, then the classiﬁcation schema can
be simpliﬁed to the initial split on AMH level, again using
Fig. 5. Classiﬁcation mosaic chart for ongoing menses (M) or
chemotherapy-related amenorrhoea (A) using serum anti-Mu¨llerian
hormone (AMH) and chronological age as predictor variables. The
primary cutoﬀ values are both for AMH, with below 3.8 pmol/L
predicting amenorrhoea and above 20.3 pmol/L predicting ongoing
menses. Between these AMH levels there is an age threshold at
38.6 years, above which amenorrhoea is predicted and below which
ongoing menses are predicted. The classiﬁcation schema has sensitivity
98.2% (one of 55 subjects known to have developed amenorrhoea
misclassiﬁed as having ongoing menses) and speciﬁcity 80.0% (four of
20 subjects with known ongoing menses misclassiﬁed as amen-
orrhoeic). After 10-fold cross-validation this schema represents the
optimal compromise between good ﬁt to the data used to construct it,
and low estimated error when used as a predictive model.
R.A. Anderson et al. / European Journal of Cancer 49 (2013) 3404–3411 340920.3 pmol/L as the cutoﬀ. In this case sensitivity is 100%,
but speciﬁcity falls to 55%.
4. Discussion
The risk of ovarian failure following chemotherapy
has previously been best predicted by the woman’s
age.3 Prospective data show substantial diﬀerences in
the prevalence of amenorrhoea in women with breast
cancer, with 70% of women aged 40 and over having
amenorrhoea after chemotherapy versus only 10% of
those under 35,4 with comparable data provided by
many similar studies. For some women, loss of ovarian
function with chemotherapy is a concern, particularly
when the beneﬁt of the therapy may be modest. There
are also emerging therapies with lower rates of amenor-
rhoea, though their eﬃcacy remains unclear31 The abil-
ity to predict more accurately that risk for an individual
woman is of increasing importance as their chances of
survival continue to improve and with societal changes
in age at childbirth. This will impact on the need to pur-
sue fertility preservation strategies in some cases,33,34
and may inﬂuence decisions on treatment regimens.
The data presented here support the value of pre-
treatment measurement of AMH, but not other hor-
monal markers of the ovarian reserve, as an
individualised predictor of the risk of amenorrhoeafollowing chemotherapy for eBC. This study thus con-
ﬁrms and validates our previous similar ﬁndings27 and
we have combined the two datasets to provide a classiﬁ-
cation mosaic. Our data conﬁrm that age is a valuable
predictor of ovarian function after chemotherapy for
eBC: as an individual predictor, it performs very well
(using a cut-oﬀ of 38.6 years). The key change in ovarian
function with age is the steady decline in the size of the
non-growing follicle pool, with the menopause occur-
ring when the pool falls below a threshold to be able
to support suﬃcient growing follicles to result in regular
ovulation.10 Thus accurate measurement of the follicle
pool is the key to assessment of individualisation of
the impact of chemotherapy on the ovary. Serum
AMH reﬂects both non-growing and growing ovarian
follicle pools15 and declines with age.35 AMH predicts
both time to, and age at, natural menopause,14 with
age an important covariate. Several studies have shown
a reduction in AMH in some childhood cancer survivors
and following cancer treatment in adult-
hood,18,21,23,24,36–38 three studies have addressed the
question of whether pretreatment AMH and other
markers of the ovarian reserve can predict post-chemo-
therapy ovarian failure. We found that AMH, but not
inhibin B, predicted long-term (4–5 year) ovarian func-
tion in women with early breast cancer,27 and others
found that both AMH and inhibin B were lower in
women with chemotherapy-associated amenorrhoea
(CRA) at 1 year after chemotherapy for early breast
cancer.26 However in a smaller study pre-chemotherapy
AMH did not diﬀer between those women who did or
did not develop CRA,28 although the ascertainment of
menses in that study was very limited.
The present data conﬁrm our previous ﬁnding that in
women with eBC, AMH is lower before treatment
(approximately fourfold on average) in women who
developed amenorrhoea after chemotherapy. Other bio-
chemical markers of the ovarian reserve (FSH and inhi-
bin B) showed no such predictive ability. Women with
amenorrhoea were also older although regression analy-
sis (including age, FSH and inhibin Bas recognised
markers of the ovarian reserve) showed that at 2 years,
only AMH was signiﬁcantly and independently related
to amenorrhoea. In the combined dataset, both AMH
and age were conﬁrmed to be predictive, with AMH
slightly more so. Overall four diﬀerent analytic methods
conﬁrmed the value of AMH with three also conﬁrming
the value of age, and from this we developed a classiﬁca-
tion mosaic. This was optimised to maximise both sensi-
tivity and speciﬁcity, but can be adapted to the clinical
scenario e.g. whether maximal sensitivity or speciﬁcity
is the most important outcome.
A strength of this study is its prospective design, thus
avoiding recall bias with careful ascertainment of men-
strual function. A limitation is that all patients had
eBC, thus its generalisability to other diseases and
3410 R.A. Anderson et al. / European Journal of Cancer 49 (2013) 3404–3411treatments is unclear, and the number of women
included is small. While several treatment regimens were
used to treat the women in this study, almost all
included cyclophosphamide, recognised to be among
the most gonadotoxic of therapies in women.5 The value
of AMH in predicting post-cancer treatment ovarian
function remains to be clearly demonstrated in younger
women, although it can be used during and following
treatment in children and adolescents.395. Conclusion
These data clearly conﬁrm that women with a lower
pretreatment AMH are more likely to develop amenor-
rhoea after chemotherapy for eBC. Thus measurement
of AMH pretreatment may guide clinicians and women
in treatment decisions and whether or not to consider
fertility preservation strategies prior to treatment.Conﬂict of interest statement
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